Report #2897362

Received May 21, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: —
Recovered: Recovered
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	—	—

Symptoms (1)

Fatigue

Symptom narrative

Severe fatigue on Day 2 following Shingrix vaccination; This non-serious case was reported by a physician via market research programs and described the occurrence of fatigue in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, 2 days after receiving Shingrix, the patient experienced fatigue (Verbatim: Severe fatigue on Day 2 following Shingrix vaccination). The outcome of the fatigue was resolved. The reporter considered the fatigue to be related to Shingrix. The company considered the fatigue to be related to Shingrix. Additional Information: GSK Receipt Date:12-MAY-2026 The batch number was not provided and we unable to contact the reporter.